You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. CCR4-IL2 Bispecific Immunotoxin for Targeted Therapy of Cutaneous T-Cell Lymphoma

    SBC: ROCK IMMUNE LLC            Topic: 102

    Abstract Cutaneous T-cell lymphoma (CTCL) is a type of extra-nodal non-Hodgkin’s lymphoma characterized by skinlesions resulting from infiltration of malignant T lymphocytes. Mycosis fungoides and Sezary syndrome are thetwo most common types of CTCL. Although treatments exist, they are mainly palliative with low response anddurability of response without any cure. The objective response rate rem ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. High-throughput functional analysis and clinical relevance of all possible variants of a gene

    SBC: HELIGENICS, INC.            Topic: NHGRI

    Modern pharmaceuticals have greatly improved the quality of life for many patients suffering a variety of illnesses. Unfortunately, among the 17 most commonly prescribed drugs, only 6 are highly effective for most patients, 5 have a modest effect, and 6 show little clinical effect. Worse still, unwanted illness and death from treatment of patients with the incorrect drug or dosage causes over 275, ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. SensiTrak: Automated Assessment of Forelimb Sensation

    SBC: VULINTUS, INC            Topic: NINDS

    Project Abstract Current common methods for measuring somatosensory function in preclinical rodent models generally rely on withdrawal responses to uncomfortable or painful stimuli. These tests can be stressful to the animal, while also yielding a high variability in measured responses, and repetitive testing in longitudinal models may even result in chronic pain states. To better understand the c ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Citizen-Science Technology for Healthy Living at Home

    SBC: Access Sensor Technologies LLC            Topic: 102

    Abstract Human exposure to air pollution is the leading environmental risk factor for premature morbidity and mortality worldwide and, in the United States (U.S.), people of color suffer from many diseases associated with exposure to air pollution at higher rates than white people. Our understanding of human exposure to air pollution is based largely on measurements of outdoor pollutant concentrat ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  5. Multi-probe minimally invasive endomicroscope

    SBC: Modendo Inc            Topic: NINDS

    PROJECT SUMMARY This project seeks to develop a multi-probe ultrathin endomicroscope to enable high-resolution imaging and photo-stimulation at multiple sites within currently inaccessible regions of the brain. The instrument will be amenable to scientific studies in model animals and a stepping stone for future medical instrumentation targeted at diagnosis and disease treatment in humans. The com ...

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  6. Novel Nanoligomer-Based Therapeutics for Inflammatory Bowel Disease

    SBC: SACHI BIOWORKS, INC.            Topic: 300

    PROJECT SUMMARY—Sachi Bioworks has developed a platform to rapidly generate Nanoligomers, a novel family of nanoparticle-bound, modified nucleic acid oligomers that up- or down-regulate the expression of selected proteins by binding to targeted DNA or mRNA. In preliminary work, Sachi demonstrated the ability to selectively target and alter the expression of immunomodulatory proteins produced by ...

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  7. SSW Works: A Virtual Learning Environment for Occupational Skin Cancer Prevention

    SBC: KLEIN BUENDEL, INC.            Topic: 102

    Americans who work outdoors are exposed to an extreme amount of solar ultraviolet radiation (UV) over a lifetime that substantially increases their risk for developing skin cancer. Annually, skin cancer is diagnosed in over 3.5 million U.S. adults, melanoma kills nearly 7,000 Americans, and treatment costs at least $8 billion. The U.S. Surgeon General has identified occupational sun safety as a na ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  8. Smartphone App to Increase and Maintain Physical Activity in African American Men (FitBrothers)

    SBC: KLEIN BUENDEL, INC.            Topic: 102

    Physical activity (PA) is a modifiable risk factor for a number of preventable chronic diseases, including cardiovascular disease, strokes, obesity, and diabetes. These conditions constitute health disparities for African American men. Behavioral interventions have proven to be effective in promoting increases in physical activity. While behavior change programs have been shown to assist participa ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  9. Long-acting Stable Glucagons for Treatment of Hyperinsulinism

    SBC: AMIDEBIO, LLC            Topic: NIDDK

    SUMMARY/ABSTRACT In severe persistent hyperinsulinism (HI), repeated hypoglycemic episodes can ultimately lead to permanent seizure disorders, learning disabilities, cerebral palsy, blindness and even death. Clinical studies have demonstrated the effectiveness of both short-term and long-term treatment with glucagon for severe forms of HI and continuous subcutaneous administration of glucagon has ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  10. A Novel Anti-inflammatory and Anti-oxidant Therapy for Treating Non-healing Diabetic Foot Ulcers

    SBC: CERIA THERAPEUTICS INC            Topic: 200

    PROJECT SUMMARYDelayed or impaired wound healing is a serious complication of diabetes, often leading to lower limb ampu- tations. By 2050, 1 in 3 Americans will develop diabetes, and up to 34% of diabetic patients will develop a diabetic foot ulcer (DFU) in their lifetime. Standard of care for DFUs includes debridement, infection control, maintaining a moist wound environment, and pressure offloa ...

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government